Medical device company Zimmer Biomet (NYSE:ZBH) will be announcing earnings results tomorrow before market hours. Here’s what to expect.

Zimmer Biomet met analysts’ revenue expectations last quarter, reporting revenues of $2.02 billion, up 4.3% year on year. It was a slower quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates.

Is Zimmer Biomet a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Zimmer Biomet’s revenue to be flat year on year at $1.89 billion, slowing from the 3.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.77 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Zimmer Biomet has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Zimmer Biomet’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. CONMED delivered year-on-year revenue growth of 2.9%, beating analysts’ expectations by 2.6%, and BD reported revenues up 4.5%, falling short of estimates by 1.5%. CONMED traded up 16.9% following the results while BD was down 18.4%.

Read our full analysis of CONMED’s results here and BD’s results here.

There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 4.9% on average over the last month. Zimmer Biomet is down 2.3% during the same time and is heading into earnings with an average analyst price target of $122.35 (compared to the current share price of $102.38).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.